Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Antiangiogenic therapy in renal cell carcinoma: from concept to reality

Nature Clinical Practice Urology volume 4, pages 74–75 (2007)Cite this article

boxed-textMotzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ratain MJ et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 2505–2512

    Article  CAS  Google Scholar 

  2. Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  CAS  Google Scholar 

  3. Motzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24

    Article  CAS  Google Scholar 

  4. Motzer RJ et al. (2006) Phase 3 randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [abstract #LBA3]. Proc Am Soc Clin Oncol 24: s2

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. R Srinivasan is a Staff Clinician and WM Linehan is the Branch Chief at the Urologic Oncology Branch of the Center for Cancer Research at the National Cancer Institute, Bethesda, MD, USA.,

    Ramaprasad Srinivasan & W Marston Linehan

Authors
  1. Ramaprasad Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Marston Linehan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W Marston Linehan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Srinivasan, R., Linehan, W. Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nat Rev Urol 4, 74–75 (2007). https://doi.org/10.1038/ncpuro0705

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0705

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing